Akums Drugs & Pharmaceuticals AKUMS
India's largest contract manufacturer of formulations for domestic pharma brands, plus trade generics and APIs
Mapped in 1 theme: Pharmaceuticals.
Where Akums Drugs & Pharmaceuticals sits in the supply chain
Akums Drugs & Pharmaceuticals appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 4,178 | 4,118 | 4,359 |
| Net profit | 1 | 344 | 256 |
Latest-year revenue ₹4,359 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Makes formulations for most large Indian branded companies - a toll on India market growth
- Scale advantage as Revised Schedule M squeezes small contract makers
Risks
- API segment losses and low ROE
- Margin pressure from customer pricing
Common questions
What does Akums Drugs & Pharmaceuticals do?
India's largest contract manufacturer of formulations for domestic pharma brands, plus trade generics and APIs.
Where does Akums Drugs & Pharmaceuticals sit in the supply chain?
Akums Drugs & Pharmaceuticals (NSE: AKUMS) is mapped in 1 supply-chain layer: CDMO & contract research (Pharmaceuticals).
Who are Akums Drugs & Pharmaceuticals' peers?
In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Syngene International, Sai Life Sciences, Anthem Biosciences, Cohance Lifesciences, Piramal Pharma and 4 more.
What is Akums Drugs & Pharmaceuticals' market cap and valuation?
As of 30 Oct 2026: market cap ₹11,516 Cr, P/E 37.8x, ROCE 14.9%, ROE 8.4%, dividend yield 0.14%.